GGrantIndex
← Leaderboards

Alexandra M Levine

University Of Southern California

$34,706,653
Attributed
$34,706,653
Total exposure
13
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.8M · FY200508
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08

Funding mix

By agency

NIH$34,706,653 · 13

By mechanism

U01$32,037,135 · 3
M01$2,086,839 · 8
K12$582,679 · 1
P30$0 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationAids TherapyKaposi'S SarcomaAids Related Neoplasm /CancerLymphomaHiv InfectionsAidsCooperative StudyTissue Resource /RegistryNonhodgkin'S LymphomaNeoplasm /Cancer ChemotherapyCombination ChemotherapyCyclophosphamideMedical Outreach /Case FindingVirus LoadHuman Immunodeficiency VirusIndinavirHuman Immunodeficiency Virus 1LamivudineFemaleExperimental DesignsFunding

Grant awards (39)

Southern California Women's Interagency HIV Study Consortium$2,910,886
U01 · FY2008 · HD · contact PI
A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY$44,463
M01 · FY2008 · RR · contact PI
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)$39,251
M01 · FY2008 · RR · contact PI
Women's Interagency HIV Study$3,993,927
U01 · FY2007 · HD · contact PI
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)$244,131
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY$35,856
M01 · FY2007 · RR · contact PI
Women's Interagency HIV Study$3,573,866
U01 · FY2006 · HD · contact PI
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)$1,111,463
M01 · FY2006 · RR · contact PI
University of Southern California$149,960
U01 · FY2006 · CA · contact PI
Women's Interagency HIV Study$3,450,189
U01 · FY2005 · HD
A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)$238,795
M01 · FY2005 · RR
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$149,157
U01 · FY2005 · CA
Women's Interagency HIV Study$3,587,840
U01 · FY2004 · HD
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$130,885
U01 · FY2004 · CA
A RANDOMIZED PHASE II TRIAL OF EPOCH$25,799
M01 · FY2004 · RR
Women's Interagency HIV Study$3,617,717
U01 · FY2003 · HD
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$265,404
U01 · FY2003 · CA
WOMENS INTERAGENCY HIV STUDY (WIHS)$3,568,374
U01 · FY2002 · HD
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$260,637
U01 · FY2002 · CA
PILOT--HEMATOLOGIC MALIGNANCY/RETROVIRAL DISEASE$0
P30 · FY2002 · CA
AMC 005--CHOP &TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS$0
M01 · FY2002 · RR
PILOT--HEMATOLOGIC MALIGNANCY/RETROVIRAL DISEASE$0
P30 · FY2002 · CA
WOMEN'S INTERAGENCY HIV STUDY (WIHS)$2,797,531
U01 · FY2001 · HD
WOMEN'S INTERAGENCY HIV STUDY (WIHS)$286,991
U01 · FY2001 · HD
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$254,849
U01 · FY2001 · CA
AIDS-ONCOLOGY CLINICAL SCIENTIST DEVELOPMENT PROGRAM$246,606
K12 · FY2001 · CA
AMC 005--CHOP &TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS$155,764
M01 · FY2001 · RR
PILOT--HEMATOLOGIC MALIGNANCY/RETROVIRAL DISEASE$0
P30 · FY2001 · CA
PILOT--HEMATOLOGIC MALIGNANCY/RETROVIRAL DISEASE$0
P30 · FY2001 · CA
AMC 005--CHOP &TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS$0
M01 · FY2001 · RR
WOMEN'S INTERAGENCY HIV STUDY (WIHS)$2,788,288
U01 · FY2000 · HD
AIDS-ONCOLOGY CLINICAL SCIENTIST DEVELOPMENT PROGRAM$336,073
K12 · FY2000 · CA
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$250,634
U01 · FY2000 · CA
AMC 005--CHOP &TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS$155,764
M01 · FY2000 · RR
AMC 005--CHOP &TRIPLE ANTIRETROVIRAL IN AIDS RELATED NON HODGKINS$35,553
M01 · FY2000 · RR
AMC010: CHOP CHEMOTHERAPY &RETUXIMAB FOR HIV NONHODGKIN'S LYMPHOMA$0
M01 · FY2000 · RR
AMC010: CHOP CHEMOTHERAPY &RETUXIMAB FOR HIV NONHODGKIN'S LYMPHOMA$0
M01 · FY2000 · RR
AMC008: IL2 FOLLOWING IFOSFAMIDE/ETOPOSIDE FOR HIV NONHODGKIN'S LYMPHOMA$0
M01 · FY2000 · RR
AMC008: IL2 FOLLOWING IFOSFAMIDE/ETOPOSIDE FOR HIV NONHODGKIN'S LYMPHOMA$0
M01 · FY2000 · RR